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Abstract
Background: We have previously demonstrated that acidic preconditioning of human endothelial colony-forming
cells (ECFC) increased proliferation, migration, and tubulogenesis in vitro, and increased their regenerative potential
in a murine model of hind limb ischemia without baseline disease. We now analyze whether this strategy is also
effective under adverse conditions for vasculogenesis, such as the presence of ischemia-related toxic molecules or
diabetes, one of the main target diseases for cell therapy due to their well-known healing impairments.
Methods: Cord blood-derived CD34+ cells were seeded in endothelial growth culture medium (EGM2) and ECFC
colonies were obtained after 14–21 days. ECFC were exposed at pH 6.6 (preconditioned) or pH 7.4 (nonpreconditioned)
for 6 h, and then pH was restored at 7.4. A model of type 2 diabetes induced by a high-fat and high-sucrose diet was
developed in nude mice and hind limb ischemia was induced in these animals by femoral artery ligation. A P value < 0.05
was considered statistically significant (by one-way analysis of variance).
Results: We found that acidic preconditioning increased ECFC adhesion and the release of pro-angiogenic molecules,
and protected ECFC from the cytotoxic effects of monosodium urate crystals, histones, and tumor necrosis factor (TNF)α,
which induced necrosis, pyroptosis, and apoptosis, respectively. Noncytotoxic concentrations of high glucose, TNFα, or
their combination reduced ECFC proliferation, stromal cell-derived factor (SDF)1-driven migration, and tubule formation
on a basement membrane matrix, whereas almost no inhibition was observed in preconditioned ECFC. In type 2 diabetic
mice, intravenous administration of preconditioned ECFC significantly induced blood flow recovery at the ischemic limb
as measured by Doppler, compared with the phosphate-buffered saline (PBS) and nonpreconditioned ECFC groups.
Moreover, the histologic analysis of gastrocnemius muscles showed an increased vascular density and reduced signs of
inflammation in the animals receiving preconditioned ECFC.
Conclusions: Acidic preconditioning improved ECFC survival and angiogenic activity in the presence of proinflammatory
and damage signals present in the ischemic milieu, even under high glucose conditions, and increased their therapeutic
potential for postischemia tissue regeneration in a murine model of type 2 diabetes. Collectively, our data suggest that
acidic preconditioning of ECFC is a simple and inexpensive strategy to improve the effectiveness of cell transplantation in
diabetes, where tissue repair is highly compromised.
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Background
Blood vessel endothelium is a key organ involved not
only in the regulation of thrombus formation but also in
tissue regeneration. Effective endothelial repair and de-
velopment of new vessels requires the contribution of
both angiogenesis, mediated by mature endothelial cells
in nearby tissues, and vasculogenesis, supported by bone
marrow-derived cells that have the potential to differen-
tiate into mature endothelial cells and are collectively re-
ferred to as endothelial progenitor cells [1]. Different
cell populations have been reported to play roles in vas-
culogenesis, but only one population commonly known
as endothelial colony-forming cells (ECFC; also known
as late outgrowth endothelial progenitor cells) represents
an endothelial cell type with potent intrinsic angiogenic
capacity and the capability of contributing to vascular
repair and de novo blood vessel formation [2, 3]. Vascu-
logenesis involves ECFC migration from the bone mar-
row in response to a chemokine gradient including
stromal cell-derived factor (SDF)1 and adhesion to the
endothelium and/or the extracellular matrix proteins.
After binding to the extracellular matrix, integrins initi-
ate signal transduction by recruiting various signaling
and adaptor proteins via their cytoplasmic domains such
as focal adhesion kinase (FAK), which plays a key role in
integrin signaling and cell migration and tissue invasion
[4]. Finally, ECFC proliferate and differentiate into ma-
ture endothelial cells and are organized into three-
dimensional structures that, together with support cells,
form the new functional vessel.
The formation of new blood vessels in adults usually
occurs in the context of an ischemic and/or inflamma-
tory microenvironment which may disturb not only
transplanted ECFC but also endogenous and local pro-
genitors due to the presence of high level of stressful sig-
nals as proinflammatory cytokines, such as tumor
necrosis factor (TNF)α, interleukin (IL)-6, -1, and -18
[5], and damage-associated molecular patterns (DAMP),
such as extracellular histones, monosodium urate (MSU)
crystals, and others. The ischemic milieu may become
even more destructive in the presence of cardiovascular
risk factors. For instance, in type 2 diabetes, a condition
associated with high glucose, obesity, and/or cholesterol,
critical limb ischemia and impaired wound healing are
frequent complications. Moreover, low levels and im-
paired functionality of circulating endothelial progenitor
cells has been reported in diabetic patients (reviewed in
[6]); these are reasons that explain why they are consid-
ered a target population for regenerative cell therapy.
We have previously demonstrated that acidic precondi-
tioning of ECFC exacerbates their angiogenic responses
including proliferation, SDF1-driven chemotaxis, and
capillary-like tubule formation, as well as revascularization
of the postischemic hind limb in mice without baseline
disease [7]. We here analyze whether this strategy is also
effective under adverse conditions for vasculogenesis, such
as the presence of ischemia-related toxic molecules or in
diabetes. We demonstrate that acidic preconditioning pro-
moted ECFC adhesion and the release of pro-angiogenic
molecules. In addition, this strategy improved ECFC
survival and angiogenic activity in the presence of proin-
flammatory and damage signals present in the ischemic
milieu, even under high glucose conditions, and improved
their therapeutic potential for postischemia tissue regener-
ation in a murine model of type 2 diabetes.
Methods
Endothelial cell cultures
Human umbilical vein endothelial cells (HUVEC) and
ECFC were obtained from umbilical cord vein and
blood, respectively, and characterized as previously de-
scribed [7, 8]. Both ECFC and HUVEC were expanded
and maintained in endothelial growth medium 2
(EGM2; Lonza, Walkersville, MD, USA).
Experimental design
The culture medium was acidified by the addition of
a precalculated volume of isotonic HCl (1 N). Acid
preconditioning was achieved by incubating ECFC at
pH 6.6 for 6 h and then the medium was replaced by
fresh EGM2 adjusted to physiologic pH (7.4) at 37 °C
in a humidified atmosphere with 5% CO2 [7]. The pH
of the medium was measured at 37 °C and averaged
7.40 ± 0.05 and 6.63 ± 0.04; pH levels remained steady
for the first 8 h [7]. ECFC were collected immediately
after preconditioning for in vitro and in vivo experi-
ments. MSU crystals (InvivoGen, San Diego, CA,
USA), human recombinant histones (New England
Biolabs, Ipswich, MA, USA), D-(+)-glucose (Sigma, St.
Louis, MO, USA) and/or TNFα (Cell Signaling
Technology, Danvers, MA, USA) were added after
preconditioning. The pan-caspase inhibitor Z-VAD-
fmk (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone; Biomol, Plymouth Meeting, PA,
USA) was added 15 min before proapoptotic stimuli.
ECFC adhesion under static conditions
ECFC (2 × 104) were stained with the fluorescent dye
carboxyfluorescein succinimidyl ester (CFSE; eBioscience,
San Diego, CA, USA) and then seeded in 48-well culture
dishes previously coated with recombinant bovine fibro-
nectin (10 μg/mL; Sigma), rat tail type-I collagen (10 μg/
mL; BD Biosciences) or TNFα-activated HUVEC. After
30 min or 2 h, plates were washed and the number of
adherent cells in five random fields was counted using
ImageJ software [9].
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ECFC adhesion under dynamic conditions
ECFC were stained with CFSE (eBioscience) and per-
fused onto a precoated chamber slide containing rat tail
type-I collagen (10 μg/mL) or TNFα-activated HUVEC.
Perfusion of ECFC was achieved using a flow chamber
(GlycoTech, Gaithersburg, MD, USA) at 0.6 mL/H
(shear force, 1 dyne/cm2) for 15 min. Cells were fixed
with paraformaldehyde (1%) for 15 min and stained
adherent cells were examined by phase-contrast confocal
fluorescence microscopy using a FV-1000 microscope
(Olympus, Tokyo, Japan). The number of adherent cells
was determined by cell count using Image J [9].
Flow cytometry studies
Cells were stained with antibodies against β1 (Santa
Cruz Biotechnology, Dallas, TX, USA), αVβ3, α5
(R&D Systems, Inc., Minneapolis, MN, USA), ICAM,
or E-selectin (BD Bioscience) for 30 min conjugated
with different fluorochromes. For caspase-3 activation,
cells were fixed, permeabilized, and then stained with
fluorescein isothiocyanate (FITC)-conjugated mono-
clonal antibody against the active fragment of
caspase-3 (BD Biosciences) for 30 min. For reactive
oxygen species (ROS) generation, ECFC were incu-
bated with dihydrorhodamine (5 mM) for 60 min at
37 °C. Sample acquisition and analysis were per-
formed by flow cytometry (FACScalibur, BD Biosci-
ences, San Jose, CA, USA) using FCS Express V3 (De
Novo Software, Glendale, CA, USA).
Western blotting
ECFC were placed onto fibronectin for 1 h and FAK
phosphorylation levels were determined by Western
blot. In brief, cell lysates were electrophoresed and
transferred to a nitrocellulose membrane. After blocking,
membranes were incubated first with an antibody
against human FAK (phospho Y397; Abcam, Cambridge,
UK) and then with horseradish peroxidase (HRP)-conju-
gated secondary antibody. Each membrane was reprobed
with an antibody against actin to calculate the relative
integrated optical density (IOD) using Gel-Pro analyzer
3.1 software.
Quantification of pro-angiogenic factor levels
The concentration of basic fibroblast growth factor
(bFGF), IL-10 (Biolegend, San Diego, CA, USA), trans-
forming growth factor (TGF)β1, IL-8, IL-4 (eBioscience),
vascular endothelial growth factor (VEGF; R&D Systems,
Inc., Minneapolis, MN, USA), platelet-derived growth
factor (PDGF; Abcam), and epidermal growth factor
(EGF; Life Technologies, Carlsbad, CA, USA) in ECFC
culture supernatants were measured by enzyme-linked
immunosorbent assay (ELISA) at the indicated time
points following the manufacturer’s instructions.
Measurement of cell death
Nuclear morphology was analyzed by fluorescence mi-
croscopy after double staining of ECFC with ethidium
bromide and acridine orange (Sigma). Phosphatidylser-
ine expression was assessed after cell staining with
Annexin V (BD) and propidium iodide (PI) and analyzed
by flow cytometry [8].
IL-1β measurement
Cells were stimulated with MSU for 24 h, and Golgi stop
(BD Bioscience; 0.65 μl/ml) was added 4 h before
fixation and permeabilization with Cytofix-Cytoperm
(BD Bioscience). Cells were then stained with anti-
human IL-1β monoclonal antibody conjugated with
FITC (Biolegend) and the percentage of positive cells
was analyzed by flow cytometry.
Measurement of cell proliferation
ECFC (1 × 104) were seeded on 96-well plates and prolif-
eration was assessed by cell counting in a Neubauer
chamber after 48 h. Counts were performed in triplicate
by one analyst under a 40× objective.
Scratch assay
Confluent ECFC monolayers were scratched by scrap-
ing with a pipette tip and the extent of cell migration
into the scratched area was photographed under the
microscope at different time points. The gap surface
area was measured by analyzing the images with Ima-
geJ software and the percentage of gap closure was
calculated as [(gap area at 0 h – gap area at x h)/gap
area at 0 h] ×100 [7].
Chemotaxis assay
Chemotaxis was examined in 24-well micro-chemotaxis
chambers with 8-μm pore size (Sigma). ECFC (1.5 × 104)
resuspended in endothelial basic medium 2 (Lonza)
supplemented with 5% fetal calf serum (FCS; Gibco,
Grand Island, NY, USA) were placed in the upper
chamber and allowed to migrate toward the lower
chamber containing the same medium with SDF1
(20 ng/mL; Abcys, Paris, France). Migration was allowed
to proceed for 6 h at 37 °C. Cells remaining on the
upper surface of the filters were mechanically removed
and then membranes were fixed with 1% formaldehyde
and stained with Giemsa. The number of migrated cells
was determined by counting under a high-power micro-
scope (Olympus) [8].
In vitro tubule formation assay
ECFC (1.5 × 104) were seeded on 96-well plates coated
with reduced growth factor basement membrane matrix
(Geltrex™; Gibco). After 18 h, tubule formation was ex-
amined by phase-contrast microscopy and the total
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number of branch points was quantified on the entire
surface of each well using ImageJ [7].
Animal studies
Eight-week-old C57BL/6 J male athymic nude mice
housed in a controlled environment were randomly di-
vided into two groups: 1) standard chow and water for
rodents (normoglycemic group); and 2) a 60% kcal high-
fat diet and 10% sucrose-supplemented water (diabetic
group). The high-fat chow contained 15% protein, 36%
fat (butter), 37% carbohydrate (18% as sucrose), minerals
(4.5%), and starch (14.5%) (SAFE AUGY, U8978P Ver-
sion 0019). Plasma glucose levels were monitored weekly
in blood from the tail plexus using a glucometer (One-
Touch Verio®IQ, LifeScan, France). After 10 weeks, mice
underwent surgery to induce unilateral hind limb ische-
mia by ligation of the right femoral artery as previously
described [7]. Nonpreconditioned or preconditioned
ECFC (1 × 105 in phosphate-buffered saline (PBS)) or PBS
alone (vehicle) were administered 5 h after occlusion in
the retro-orbital plexus, and the ischemic/normal limb
blood flow ratio was determined on days 7 and 14 using
the laser Doppler perfusion imaging system PeriScan
Pim3 (Perimed, Crappone, France). Gastrocnemius
muscles were surgically removed for histological analysis.
Vascular density was determined by counting the number
of blood vessels in entire Masson’s trichrome sections and
were expressed as vessels per mm2. Inflammation score
(arbitrary units) was determined by analyzing the presence
of vacuoles, centered and hypertrophic nuclei, and
leukocyte infiltrate in hematoxylin and eosin (H&E)
sections.
Statistical analysis
Results are expressed as means ± SEM. Significant dif-
ferences (P < 0.05) were identified by one-way analysis of
variance (ANOVA) followed by the Bonferroni test using
the GraphPad software package (PRISM Version 5.0,
San Diego, CA, USA).
Results
Preconditioned ECFC exhibit enhanced adhesive
properties and release of pro-angiogenic cytokines
We have previously demonstrated that acidic precondi-
tioning increased ECFC proliferation, migration, and tu-
bule formation [7]. We now extend those findings and
demonstrate that this strategy also promotes other ECFC
angiogenic responses. Preconditioned ECFC exhibited
both enhanced nascent (30 min) and focal (2 h) adhe-
sions to fibronectin, type-I collagen, and TNFα-activated
HUVEC either under static conditions (Fig. 1a) or
physiological shear stress conditions (Fig. 1b). These en-
hanced adhesive abilities were associated with higher
FAK phosphorylation levels on Tyr576 triggered by
fibronectin (Fig. 1c), and a slight but significant increase
in integrin α5, ICAM, and E-selectin, but not β1 or
αVβ3 (Fig. 1d).
In addition, we found that acidic preconditioning en-
hanced the release of several pro-angiogenic and anti-
inflammatory molecules. While higher levels of TGFβ1,
bFGF, PDGF, IL-8, IL-4, VEGF, and IL-10 were detected
in supernatants from preconditioned ECFC, EGF showed
no significant differences between treatments (Fig. 1e).
In agreement with our previous study [7], the formation
of capillary-like structures was highly increased (64 ± 9%)
when ECFC were placed on Geltrex™ matrix immediately
after preconditioning. Interestingly, we now observed
that the angiogenic advantage of preconditioned
ECFC remains intact after 8 h post-preconditioning
(exhibiting an increase of 59 ± 7%), then decay after
18 h (39 ± 3%) and 24 h (21 ± 4%), and finally is com-
pletely lost after 48 h (1 ± 5%).
Acidic preconditioning protects ECFC from death induced
by different cytotoxic stimuli
Endothelial progenitor cells that migrate to injured tis-
sues encounter a hostile milieu of stress signals and
DAMP that might undermine its survival and function-
ality. Because MSU crystals are considered one of the
most abundant DAMP in ischemic and necrotic tissues
[10, 11], we first analyzed their effect on ECFC and
found that MSU crystals triggered ECFC death in a con-
centration- and time-dependent manner (Fig. 2a, b). Nu-
clear morphology changes and the observation that
cellular death was independent of caspases, NLRP3
inflammasome activation, or ROS formation indicated
that MSU induced necrosis of ECFC (Fig. 2c–g).
The fact that stress signals that are highly present in
the inflammatory and ischemic microenvironment can
trigger different programs of cellular death prompted us
to elucidate whether acidic preconditioning protects
ECFC from three different death stimuli: MSU (necrosis)
, TNFα (apoptosis), and histones (pyroptosis). Interest-
ingly, MSU-, TNFα-, and histone-mediated cytotoxicity
were significantly reduced in preconditioned ECFC when
compared with nonpreconditioned ECFC (Fig. 3a). Simi-
lar results were observed by flow cytometry after
annexin V and PI staining (Fig. 3b).
Although diabetes, especially the type 2 class, is one of
the main target diseases for cell therapy due to its well-
known healing impairments, studies regarding the effect
of high glucose conditions on ECFC survival are scarce
and controversial [12]. Our results revealed that high
glucose alone failed to induce ECFC death (Fig. 3c).
However, TNFα-induced apoptosis of ECFC was
significantly increased under high glucose conditions
and these effects were observed in both untreated and
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preconditioned ECFC, although cytotoxicity was lower in
the latter (Fig. 3c). MSU- or histone-induced toxicity was
not significantly affected by glucose (Additional file 1).
Mannitol (as an osmotic control) and normal glucose con-
centration (5 mM) were run in parallel and, in both cases,
results were no different from untreated cells (data not
shown).
ECFC angiogenic activity is enhanced by acidic
preconditioning under proinflammatory and high
glucose conditions in vitro
We next analyzed whether acid preconditioning, in
addition to its cytoprotective effect, improved the angio-
genic responses of ECFC exposed to inflammatory but
nontoxic concentrations of TNFα in the presence or
Fig. 1 Acidic preconditioning increased endothelial colony-forming cell (EFCF) adhesion and pro-angiogenic factor release. a Nonpreconditioned
(npECFC) or preconditioned ECFC (pECFC) (grey and black bars, respectively) were seeded onto fibronectin, collagen type I, or TNFα-activated
human umbilical vein endothelial cells (HUVEC) and, after 30 min or 2 h, the number of adherent cells was counted (n = 5). b ECFC were perfused
onto collagen or TNFα-activated HUVEC for 15 min at shear force 1 dyn/cm2 and the number of adherent cells was counted (n = 4). c ECFC were
seeded onto fibronectin for 30 min and focal adhesion kinase (FAK) phosphorylation was determined by Western blot. Each membrane was
reprobed with anti-actin antibody to calculate the relative integrated optical density (IOD) (n = 4). d ECFC were stained with antibodies against
ICAM, E-selectin, α5, β1, or αVβ3 and then analyzed by flow cytometry (n = 3). e Interleukin (IL)-8, transforming growth factor (TGF)β1, basic
fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and IL-4 or IL-10, vascular endothelial growth factor (VEGF) and epidermal
growth factor (EGF) cytokines were measured in the supernatants of npECFC or pECFC after 24 or 48 h, respectively (n = 5). *p < 0.05 vs npECFC.
AU, arbitrary units; MFI, mean fluorescence intensity
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absence of high glucose. ECFC adhesion was not signifi-
cantly affected by high glucose and/or TNFα, except for
the improved adhesion of preconditioned ECFC to acti-
vated HUVEC which was significantly reduced by high
glucose or TNFα and completely abrogated by their
combination (Additional file 2).
Regarding ECFC proliferation, TNFα alone induced
a significant antiproliferative effect in nonprecondi-
tioned cells, which was more pronounced when com-
bined with high glucose, whereas almost no inhibition
was observed in preconditioned ECFC (Fig. 4a). Simi-
lar results were observed when tubule formation on
Geltrex™ matrix was assessed (Fig. 4b, c). No prolifer-
ation or tubule formation was observed when ECFC
were cultured in the cytokine-free medium EBM2
(negative control). We also found that the extent of
proliferation and migration into the cell monolayer
scratched area after 18 h was significantly impaired
by TNFα alone or combined with high glucose in un-
treated ECFC, while these effects were significantly
prevented by acidic preconditioning (Fig. 5a, b). A
similar gap closure inhibition was detected after 6 h
when proliferation barely contributes to this process,
revealing a direct suppressive effect on cell migration
Fig. 2 Monosodium urate (MSU) induced endothelial colony-forming cell (EFCF) necrosis. a ECFC were treated with MSU at the indicated concentration
and the cell death was analyzed by fluoresce microscopy after 24 h (n= 5). b Kinetics of ECFC death were studied by fluorescence microscopy (n= 4). c
Representative images of viable (V) and necrotic (N) cells are shown. Original magnification, 1200×. Scale bar = 10 μm. d The percentage of cell death was
measured by fluorescence microscopy in the presence or absence of Z-VAD-fmk (30 μM). The percentage of positive cells for active
caspase-3 (e), interleukin (IL)-1β levels (f), and reactive oxygen species (ROS) formation (g) were analyzed by flow cytometry after 24 h
(n = 3). *p < 0.05 vs untreated. NS, not significant
Mena et al. Stem Cell Research & Therapy  (2018) 9:120 Page 6 of 13
mediated by TNFα and high glucose, which was again
significantly lower in preconditioned ECFC (Fig. 5a,
b). These results were confirmed by analyzing ECFC
migration in response to SDF1 using transwell inserts
(Fig. 5c).
Postischemia tissue regeneration is improved by
preconditioned ECFC in normoglycemic and type 2
diabetic mice
We have previously demonstrated that after hind limb
ischemia induction in normoglycemic mice blood flow
Fig. 3 Preconditioned endothelial colony-forming cells (EFCF) are more resistant to DAMP- or TNFα-induced cell death. Nonpreconditioned or
preconditioned ECFC (npECFC or pECFC, respectively) were incubated with monosodium urate (MSU), tumor necrosis factor (TNF)α, or histones at
the indicated concentrations. a The nuclear morphology was analyzed by fluorescence microscopy and (b) the percentage of annexin V and
propidium iodide (PI) double-positive cells was measured by flow cytometry after 24 h (n = 6). c ECFC were incubated with high glucose, TNFα,
or their combination and cell death was analyzed after 24 h (n = 6). *p < 0.05 vs untreated npECFC; #p < 0.05 vs npECFC with the same treatment
Fig. 4 Acidic preconditioning improved endothelial colony-forming cell (EFCF) proliferation and tubule formation under adverse conditions.
Nonpreconditioned or preconditioned ECFC (npECFC or pECFC, respectively) were treated with high glucose, tumor necrosis factor (TNF)α, or
their combination, and the different angiogenic responses were measured. a Cell counts were performed after 48 h using a Neubauer chamber
(n = 4). b Cells were seeded on Geltrex™ matrix and the number of branch points per field was measured after 18 h. c Representative images of
six different experiments. Original magnification, 40×. *p < 0.05 vs untreated npECFC; #p < 0.05 vs npECFC with the same treatment; &p < 0.05 vs
TNFα or glucose alone
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recovery was significantly increased by the administra-
tion of preconditioned ECFC (versus nonprecondi-
tioned ECFC- and PBS-treated groups) as measured
by Doppler scanning [7]. We now confirm and extend
our previous findings, performing a deeper analysis of
the muscle histology. In agreement with our previous
study, Doppler analysis showed that a single intraven-
ous injection of preconditioned ECFC increased the
ischemic to nonischemic leg blood flow ratio relative
to nonpreconditioned ECFC- or PBS-treated mice
(Fig. 6a). Moreover, histologic analysis of the gastro-
cnemius muscles at high and low magnifications (Fig.
6b and Additional file 3, respectively) revealed that
the injection of nonpreconditioned ECFC reduced
local inflammation (Fig. 6c) and had no effect on vas-
cular density (Fig. 6d) when compared with PBS-
treated animals. Interestingly, both parameters were
significantly improved after administration of precon-
ditioned ECFC.
Type 2 diabetic patients are a target population for cell
therapy since critical limb ischemia and impaired wound
healing are frequent complications. According to the se-
verity of the disease, these patients might develop diabetic
foot syndrome, a clinical entity that might result in infec-
tion and amputation [13]. Having shown in vitro that
acidic preconditioning improves the angiogenesis activity
of ECFC even under inflammatory or hyperglycemic
conditions, we next aimed to elucidate whether precondi-
tioning is an effective strategy to improve postischemia
tissue regeneration in a murine model of type 2 diabetes.
Nude mice at the age of 8 weeks were fed either chow or
diabetogenic diet for a total of 10 weeks, when hypergly-
cemia was established (Table 1). Despite the similar total
body fat in both groups (Table 1), the amount of epididy-
mal, inguinal, and interscapular fat was higher in diabetic
mice compared with normoglycemic ones. According to
Doppler analysis, the muscle perfusion index in diabetic
animals was similar to normoglycemic mice after 7 days,
but significantly lower after 14 days (Fig. 6a). Nonprecon-
ditioned ECFC significantly enhanced foot perfusion in
the diabetic ischemic limb compared with PBS-treated
animals after 7, but not 14, days postischemia,
whereas preconditioned ECFC further improved blood
flow at both 7 and 14 days compared with the PBS
and nonpreconditioned ECFC groups (Fig. 6a). In
addition to reducing blood flow, histologic analysis of
the gastrocnemius muscles at high and low magni-
fications (Fig. 6b and Additional file 3, respectively)
showed that administration of preconditioned ECFC
significantly diminished the inflammation score (Fig.
6c) and increased vascular density (Fig. 6d) compared
with the nonpreconditioned ECFC or PBS groups. Of
note, there were no episodes of lower limb necrosis
or defects in ambulation in any group.
Fig. 5 Acidic preconditioning improves endothelial colony-forming cell (EFCF) migration under stressful conditions. Nonpreconditioned or
preconditioned ECFC (npECFC or pECFC, respectively) were treated with high glucose, tumor necrosis factor (TNF)α, or their combination, and the
different angiogenic responses were measured. a The extent of cell migration into the scratched area was measured after 0, 6, and 18 h (n = 5). b
Images show the kinetic of gap closure in npECFC or pECFC treated with both high glucose and TNFα. Original magnification, 40×. c Chemotaxis
in response to SDF1 (20 ng/ml) was determined using transwell inserts. The number of migrated cells was counted after 6 h (n = 4). *p < 0.05 vs
untreated npECFC; #p < 0.05 vs npECFC with the same treatment; &p < 0.05 vs TNFα or glucose alone
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Discussion
ECFC recruitment to sites of neoangiogenesis involves
ECFC migration and adhesion to activated endothelium,
as well as a direct interaction with the extracellular
matrix—key steps to a successful engraftment. Cell
adhesion is initiated by the formation of unstable
receptor-matrix complexes (nascent adhesions) that might
disassemble and disappear or further mature into stable
focal adhesions [4]. Since the regulation of ECFC adhesion
by acidic preconditioning was not analyzed in our former
study [7], we now performed a deep analysis of this
process and provided strong evidence that acidic precon-
ditioning of ECFC enhanced nascent and focal adhesion
to fibronectin, collagen, and activated HUVEC under
static and physiological shear stress conditions. Interest-
ingly, higher levels of FAK phosphorylation were found in
preconditioned ECFC compared with nonpreconditioned
ECFC, reinforcing the idea that focal adhesion is aug-
mented by acidosis. FAK is an integrin-dependent tyrosine
phosphorylated protein localized at focal adhesion sites
that, beyond the classic role in adhesion and migration,
also regulates several biological processes including cell
motility, differentiation, angiogenesis, and survival via the
FAK/Src/Paxillin cascade [4, 14]. Indeed, endothelial
integrins might be responsible, at least in part, for the
acidic preconditioning-mediated pro-angiogenic effect
since a higher expression of the integrin α5, involved in
the interaction between ECFC and matrix proteins, was
found in preconditioned ECFC. Moreover, ICAM and E-
selectin, which mediate their contact with leukocytes and
endothelial cells, were also elevated after this procedure.
The release of pro-angiogenic proteins from ECFC
was another pro-angiogenic function improved by pre-
conditioning. bFGF, TGFβ1, IL-8, IL-4, VEGF, PDGF,
Fig. 6 Acidic preconditioning enhanced endothelial colony-forming cell (EFCF)-mediated neovascularization in ischemic hind limbs of normoglycemic
and diabetic mice. Phosphate-buffered saline (PBS), and nonpreconditioned or preconditioned ECFC (npECFC or pECFC, respectively) were infused
intravenously in normoglycemic and type 2 diabetic (T2D) mice 5 h after ischemia-inducing surgery. a Perfusion index was calculated by Doppler
analysis after 7 and 14 days postischemia. Representative images of T2D animals are shown. b Histologic analysis of gastrocnemius muscles, stained
with hematoxylin and eosin (H/E) or Masson’s trichrome, was performed after 14 days postischemia. Original magnification, 400×. Scale bar = 80 μm
c Inflammation score was calculated in H/E stained sections. d Vascular density was measured in Masson’s trichrome stained sections. n = 6 per group.
*p < 0.05 vs PBS; #p < 0.05 vs npECFC; &p < 0.05 vs the same treatment in the normoglycemic group; ¥p < 0.05 vs no ischemia. AU, arbitrary units
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and IL-10 were highly increased in preconditioned ECFC
supernatants, while EGF was also secreted with no sig-
nificant differences between groups. The paracrine ac-
tion of ECFC has been underestimated when compared
with early endothelial progenitor cells, which have a
hematopoietic origin and release enormous levels of cy-
tokines and growth factors. Nonetheless, it is currently
well known that the ECFC secretome is crucial for the
regeneration of damaged tissues [2].
Despite the therapeutic potential of ECFC, clinical
studies are still inconclusive regarding the effectiveness
of ECFC administration for tissue regeneration. One of
the limitations of this practice is the low viability of the
transplanted cells in the ischemic and inflammatory
microenvironment, probably due to high levels of harm-
ful signals known as DAMP, as well as the presence of
cardiovascular risk factors. In fact, we have previously
demonstrated that extracellular histones induced mostly
pyroptosis of ECFC [8], while TNFα is a well-known
proapoptotic cytokine [15, 16]. Under ischemia condi-
tions, intracellular uric acid formation is enhanced [17]
and a vast amount of this substance is released after cell
death forming MSU crystals, one of the most abundant
DAMP in the ischemic microenvironment. We here
show that MSU induced ECFC necrosis. A programmed
cell death process was disregarded since the MSU toxic
effect was independent of caspases, NLRP3 inflamma-
some activation, and ROS formation. Interestingly, we
show that, despite the different cell death program trig-
gered by each stimulus, acidic preconditioning protects
ECFC with great efficiency from the harmful effects of
MSU, TNFα, and extracellular histones.
The proinflammatory cytokine TNFα is highly aug-
mented in plasma and tissues of patients with several car-
diovascular and inflammatory diseases and is considered a
risk factor for developing these clinical conditions [18].
Most studies that have investigated the effect of this mol-
ecule on endothelial progenitor cells agree that high con-
centrations of TNFα (> 20 ng/mL) induce apoptosis
whereas low concentrations (~ 10 ng/mL) reduce angio-
genic responses such as proliferation and tubulogenesis [15,
16, 18]. Following same line of evidence, we here found that
TNFα exerted a significant proapoptotic effect at a concen-
tration of 50 ng/mL and, at non-toxic levels (10 ng/mL),
inhibited ECFC proliferation, migration, and tubule forma-
tion. On the other hand, although diabetes is considered
one of the main target diseases for cell therapy due to the
frequent ischemic events and wound healing impairments,
studies regarding the effect of high glucose conditions on
ECFC survival are scarce and controversial. While some
studies described a direct cytotoxic effect [19, 20], others
are in full agreement with our findings showing that high
glucose alone failed to induce apoptosis but inhibited ECFC
angiogenic activity [12, 18, 21]. We also found that high
glucose potentiated apoptosis triggered by TNFα, an effect
that was significantly prevented by acidic preconditioning.
It has been previously shown that TNFα impaired
ECFC angiogenic functions through upregulation of p38
MAPK and downregulation of AKT/PI3K [22, 23], and
that high glucose inhibited ECFC proliferation and dif-
ferentiation in a p38 MAPK-dependent manner [19, 20].
Since we have previously demonstrated that acidic pre-
conditioning of ECFC augmented tubulogenesis through
p38 MAPK inhibition and increased proliferation
through AKT/PI3K activation [7], it is conceivable that
these pathways are responsible for acidosis-mediated
ECFC protection from TNFα and/or high glucose anti-
angiogenic effects.
We showed that acidic preconditioning of late out-
growth endothelial progenitor cells derived from cord
Table 1 Mice glycemia and weight evolution
Weeks of diet Glycemia (g/L) Weight (g)
Normoglycemic Type 2 diabetes Normoglycemic Type 2 diabetes
1 1.55 ± 0.04 1.43 ± 0.05 29.49 ± 0.28 28.81 ± 0.29
2 1.53 ± 0.05 1.42 ± 0.05 30.19 ± 0.29 29.81 ± 0.34
3 1.30 ± 0.05 1.31 ± 0.05 32.94 ± 0.37 30.30 ± 0.35
4 1.36 ± 0.04 1.11 ± 0.05 32.85 ± 0.39 32.55 ± 0.38
5 1.45 ± 0.07 1.74 ± 0.07* 33.49 ± 0.55 33.67 ± 0.40
6 1.24 ± 0.05 1.85 ± 0.06* 34.36 ± 0.57 36.00 ± 0.62
7 1.42 ± 0.09 1.93 ± 0.05* 35.93 ± 0.88 36.41 ± 0.63
8 1.52 ± 0.08 2.20 ± 0.05* 35.54 ± 0.60 36.01 ± 0.53
9 1.47 ± 0.05 2.03 ± 0.06* 36.23 ± 0.75 35.57 ± 0.62
10 (15 min postsurgery) 1.53 ± 0.07 2.40 ± 0.08* 35.45 ± 0.87 35.58 ± 0.90
11 (7 days postsurgery) 1.54 ± 0.03 2.24 ± 0.05* 33.51 ± 0.60 35.55 ± 0.60
12 (14 days postsurgery) 1.26 ± 0.06 2.13 ± 0.07* 35.13 ± 0.58 35.70 ± 0.62
*p < 0.05 vs normoglycemic by ANOVA
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and peripheral blood enhances their angiogenic activity
in vitro and increased blood flow (Doppler analysis) in a
hind limb ischemia model in C57BL/6 J athymic nude
mice with no baseline disease [7]. In the present study,
we further extended those findings by demonstrating
that preconditioned ECFC not only augmented blood
flow but also increased vascular density and reduced the
inflammation score as revealed by histological analysis of
gastrocnemius muscle sections. Although endogenous
recovery from ischemia in the PBS-treated animals at
day 14 was elevated, this is expected for immunocom-
promised mice in general and this mouse strain in par-
ticular [24]. Obesity-related disorders, including diabetes
and hypertension, are associated with impaired endothe-
lial progenitor cell functions [25]. In fact, their
mobilization in response to injury is impaired in diabetic
mice, and glucose-intolerant individuals exhibit lower
levels of circulating endothelial progenitor cells [26, 27].
A chronic high-fat high-sucrose (HFHS) diet is a well-
established method to promote obesity and insulin re-
sistance, resulting in a type 2 diabetes-like condition
(hyperglycemia) in murine models [28, 29]. Although it
has been extensively described in the wild-type C57BL/
6 J strain, we here described for the first time that this
model can be successfully developed in C57BL/6 J athy-
mic nude mice. Blood glucose levels in these mice were
similar to the wild type after 10–12 weeks of HFHS diet
[28, 30]. Regarding the body weight, although a 20–30%
increase was reported in the existing models [28, 30], no
differences were observed between groups in our nude
mice after 10 weeks of treatment, but a significant
weight gain (24%) in diabetic animals was detected after
18 weeks of diabetogenic diet. Hyperactivity was a fre-
quent observation within the first weeks of a high-fat
and high-sugar regimen, which may explain why weight
gain was slower than expected; however, an increased
amount of adipose tissue was evident in diabetic mice
macroscopically (epididymal, inguinal, and interscapular
fat accumulation) and microscopically (lipid vacuoles
within the muscle fibers). The diabetogenic diet also re-
duced blood flow recovery after hind limb ischemia,
which was significantly different from normoglycemic
mice only after 14 days by Doppler scanning. Muscle
histology was consistent with Doppler analysis as ische-
mia induced an exacerbated inflammatory response and
lower vascular density compared with nondiabetic ani-
mals. Although administration of untreated ECFC ame-
liorated the impairment of revascularization and tissue
inflammation in diabetic animals, these effects were sig-
nificantly improved after treatment with preconditioned
ECFC. Moreover, preconditioned ECFC was the only
treatment that significantly restored blood flow in dia-
betic gastrocnemius muscles at 14 days after ischemia.
In addition to its predictable pro-angiogenic activity, our
progenitor cells also exhibited anti-inflammatory effects
reflected by small numbers of vacuoles, centered and
hypertrophic nuclei, and infiltrated leukocyte in gastro-
cnemius muscles. Our findings showing that acidic pre-
conditioning increased the release of IL-4, TGFβ1, and
IL-10 led us to speculate that it might be related to a
paracrine action of these progenitors which, once
engrafted, increase the local levels of anti-inflammatory
cytokines. In this sense, it has been reported that endo-
thelial progenitor cells improved the neurological func-
tion of rats with intracerebral hemorrhage by decreasing
pro-inflammatory cytokines such as IFN-γ, IL-6, and
TNFα, and increasing anti-inflammatory cytokines such
as TGFβ1 and IL-10 [31]. Moreover, Moubarik et al. sug-
gested that endothelial progenitor cell-mediated attenu-
ation of neurological injury after middle cerebral artery
occlusion may include upregulation of neural protective
cytokines, such as IGF-1, and downregulation of
proBDNF, which is a proinflammatory factor [32].
Altogether, our findings show that acidic precondition-
ing improved ECFC survival and angiogenic activity in
the presence of proinflammatory and damage signals
highly present in the ischemic milieu and is an effective
strategy to promote postischemia tissue regeneration in
a murine model of type 2 diabetes.
Conclusions
In the present study, we demonstrated that acidic pre-
conditioning of human ECFC promoted adhesion and
the release of proangiogenic molecules. In addition, this
strategy attenuated the harmful effect induced by several
molecules that are highly increased in the ischemic and
inflammatory microenvironment, including MSU, extra-
cellular histones, and TNFα, despite the different cell
death programs triggered by each stimulus. Precondi-
tioned ECFC exhibited an increased survival, in vitro ex-
pansion capacity, and angiogenic activity. This
cytoprotective effect was also observed under high glu-
cose conditions in vitro and, more interestingly, in a
murine model of type 2 diabetes, where preconditioned
ECFC were more efficient than untreated cells in restor-
ing hind limb revascularization and reducing ischemia-
related tissue damage and inflammation.
Additional files
Additional file 1: ECFC cell death induced by histones or MSU is not
affected under high glucose conditions. Nonpreconditioned ECFC
(npECFC) were incubated with histones (A) or MSU crystals (B) at the
indicated concentrations, in the presence or absence of high glucose,
and cell death was analyzed after 24 h (n = 3–5). (DOCX 135 kb)
Additional file 2: ECFC adhesion under proinflammatory and high
glucose conditions. Nonpreconditioned or preconditioned ECFC (npECFC
or pECFC, respectively) were incubated with high glucose, TNFα, or their
combination, and seeded onto fibronectin, collagen, or TNFα-activated
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HUVEC. After (A) 30 min or (B) 2 h, the number of adherent cells was
counted. Results are expressed as percentage of nonpreconditioned ECFC
(n = 5). *p < 0.05 vs untreated npECFC. #p < 0.05 vs npECFC with the same
treatment. (DOCX 478 kb)
Additional file 3: Histologic analysis of gastrocnemius muscles. PBS,
nonpreconditioned, or preconditioned ECFC (npECFC or pECFC, respectively)
were infused intravenously in normoglycemic and type 2 diabetic (T2D) mice
5 h after ischemia-inducing surgery. Histologic analysis of gastrocnemius
muscles, stained with hematoxylin and eosin (H/E) or Masson’s trichrome, was
performed after 14 days postischemia in normoglycemic and type 2 diabetic
(T2D) mice (n= 6 per group). Original magnification, 100×. Scale bar = 20 μm.
(DOCX 1573 kb)
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